Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Outcome of an enhanced diagnostic pipeline for patients suspected of inherited thrombocytopenia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Response to: Patient-centred medical education: A proposed definition

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Clara M A de Bruijn
  • Frédéric Millot
  • Meinolf Suttorp
  • Marina Borisevich
  • Paul Brons
  • Birgitte Lausen
  • Eveline S J M de Bont
Vis graf over relationer

This international study aimed to assess the effect of imatinib discontinuation in paediatric patients with chronic myeloid leukaemia (CML) after deep molecular remission (DMR) had been achieved and maintained for at least 2 years. The primary endpoint of this analysis was the molecular relapse-free survival, estimated by the non-parametric Kaplan-Meier method. Major endpoint was the estimated rate of patients without molecular relapse at 6 months. Fourteen patients were enrolled; 4 patients maintained DMR with a follow-up of 24 (two patients), 34 and 66 months, respectively, whereas 10 patients relapsed. All molecular relapses occurred within 6 months (median 3 months, range 1-6) after imatinib discontinuation. The overall probability of maintaining DMR at 6 months was 28·6%. No parameters associated with molecular relapse could be identified. Keeping in mind the rarity of paediatric CML, which contributed to the small size of the cohort, our findings illustrate that imatinib cessation after sustained DMR is successful in only limited numbers of patients, whereas much higher rates are reported in adult patients. Further research is needed to extend the cohort of paediatric CML patients who might achieve treatment-free remission with an ideal prerequisite of predicting the occurrence of molecular relapse l after imatinib cessation.

OriginalsprogEngelsk
TidsskriftBritish Journal of Haematology
Vol/bind185
Udgave nummer4
Sider (fra-til)718-724
Antal sider7
ISSN0007-1048
DOI
StatusUdgivet - 2019

Bibliografisk note

© 2019 British Society for Haematology and John Wiley & Sons Ltd.

ID: 59088082